{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:52:54Z","timestamp":1778172774944,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,22]]},"DOI":"10.7759\/cureus.86556","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T23:40:14Z","timestamp":1750635614000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Tofacitinib in the Management of Ankylosing Spondylitis: A Comprehensive Systematic Review"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Burhanuddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikandar Abbas","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Dhami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundus","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Wali","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Muaz","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Uzair","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52559","article-title":"Diagnosis and treatment of ankylosing spondylitis","volume":"16","author":"Agrawal P","year":"2024","unstructured":"Agrawal P, Tote S, Sapkale B. Diagnosis and treatment of ankylosing spondylitis. Cureus. 2024, 16:e52559. 10.7759\/cureus.52559","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean LE","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014, 53:650-7. 10.1093\/rheumatology\/ket387","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu W","year":"2019","unstructured":"Zhu W, He X, Cheng K, et al.. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019, 7:22. 10.1038\/s41413-019-0057-8","journal-title":"Bone Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S37325","article-title":"The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis","volume":"7","author":"Tsui FW","year":"2014","unstructured":"Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD. The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. Appl Clin Genet. 2014, 7:105-15. 10.2147\/TACG.S37325","journal-title":"Appl Clin Genet"},{"key":"ref5","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge JA","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al.. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016, 34:318-28.","journal-title":"Clin Exp Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002253","article-title":"Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Navarro-Comp\u00e1n V","year":"2022","unstructured":"Navarro-Comp\u00e1n V, Wei JC, Van den Bosch F, et al.. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022, 8:e002253. 10.1136\/rmdopen-2022-002253","journal-title":"RMD Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001042","article-title":"Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis","volume":"6","author":"Ogdie A","year":"2020","unstructured":"Ogdie A, de Vlam K, McInnes IB, et al.. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020, 6:e001042. 10.1136\/rmdopen-2019-001042","journal-title":"RMD Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al.. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017, 76:1340-7. 10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46391","article-title":"Do tofacitinib generics exhibit conventional synthetic disease-modifying anti-rheumatic drug and non-steroidal anti-inflammatory drug-sparing ability in the management of axial spondyloarthritis?","volume":"15","author":"Ganapati A","year":"2023","unstructured":"Ganapati A, Arya S, Gupta N, et al.. Do tofacitinib generics exhibit conventional synthetic disease-modifying anti-rheumatic drug and non-steroidal anti-inflammatory drug-sparing ability in the management of axial spondyloarthritis?. Cureus. 2023, 15:e46391. 10.7759\/cureus.46391","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych WP","year":"2018","unstructured":"Maksymowych WP, van der Heijde D, Baraliakos X, et al.. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018, 57:1390-9. 10.1093\/rheumatology\/key104","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00564-y","article-title":"Tofacitinib reduces spinal inflammation in vertebral bodies and posterolateral elements in ankylosing spondylitis: results from a phase 2 trial","volume":"10","author":"\u00d8stergaard M","year":"2023","unstructured":"\u00d8stergaard M, Wu J, Fallon L, et al.. Tofacitinib reduces spinal inflammation in vertebral bodies and posterolateral elements in ankylosing spondylitis: results from a phase 2 trial. Rheumatol Ther. 2023, 10:1001-20. 10.1007\/s40744-023-00564-y","journal-title":"Rheumatol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00711-z","article-title":"Efficacy and safety of tofacitinib in patients with psoriatic arthritis or ankylosing spondylitis by cigarette smoking status","volume":"11","author":"Ogdie A","year":"2024","unstructured":"Ogdie A, Kristensen LE, Soriano ER, et al.. Efficacy and safety of tofacitinib in patients with psoriatic arthritis or ankylosing spondylitis by cigarette smoking status. Rheumatol Ther. 2024, 11:1649-64. 10.1007\/s40744-024-00711-z","journal-title":"Rheumatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00726-6","article-title":"Tofacitinib efficacy\/safety in patients with ankylosing spondylitis by baseline body mass index: a post hoc analysis of phase 2\/3 trials","volume":"12","author":"Norton H","year":"2025","unstructured":"Norton H, Sliwinska-Stanczyk P, Hala T, et al.. Tofacitinib efficacy\/safety in patients with ankylosing spondylitis by baseline body mass index: a post hoc analysis of phase 2\/3 trials. Rheumatol Ther. 2025, 12:67-84. 10.1007\/s40744-024-00726-6","journal-title":"Rheumatol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03313-w","article-title":"Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis","volume":"26","author":"Navarro-Comp\u00e1n V","year":"2024","unstructured":"Navarro-Comp\u00e1n V, Deodhar A, Bahiri R, Bushmakin AG, Cappelleri JC, Rammaoui J. Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis. Arthritis Res Ther. 2024, 26:105. 10.1186\/s13075-024-03313-w","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00727-5","article-title":"Improvement of fatigue in patients with ankylosing spondylitis receiving tofacitinib: analyses of a phase 3 randomized controlled trial","volume":"12","author":"Gossec L","year":"2025","unstructured":"Gossec L, Walsh JA, Sengupta R, et al.. Improvement of fatigue in patients with ankylosing spondylitis receiving tofacitinib: analyses of a phase 3 randomized controlled trial. Rheumatol Ther. 2025, 12:85-98. 10.1007\/s40744-024-00727-5","journal-title":"Rheumatol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00570-0","article-title":"Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis","volume":"10","author":"Kristensen LE","year":"2023","unstructured":"Kristensen LE, Navarro-Comp\u00e1n V, Magrey M, et al.. Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis. Rheumatol Ther. 2023, 10:1073-87. 10.1007\/s40744-023-00570-0","journal-title":"Rheumatol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369657-efficacy-and-safety-of-tofacitinib-in-the-management-of-ankylosing-spondylitis-a-comprehensive-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T23:40:15Z","timestamp":1750635615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369657-efficacy-and-safety-of-tofacitinib-in-the-management-of-ankylosing-spondylitis-a-comprehensive-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.86556","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,22]]}}}